# Clinical Study of Divozilimab in Patients With Systemic Scleroderma

> **NCT05726630** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 152 (actual)

## Conditions studied

- Systemic Scleroderma

## Interventions

- **DRUG:** Divozilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05726630
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-26
- **Primary completion:** 2024-10-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726630, "Clinical Study of Divozilimab in Patients With Systemic Scleroderma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05726630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*